Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSage trial
jRCTs051260193Phase 2Recruiting
- Start
- Oct 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab, zolbetuximab, nivolumab, pembrolizumab, docetaxel and 2 more in gastric cancer (GC) and esophagogastric junction cancer (4 arms). Primary endpoint: Median progression-free survival. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCTs051260193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260193.